Potenciális antitumor hatású FGFR inhibitorok fejlesztése.

Translated title of the contribution: [Developing FGFR inhibitors as potential anti-cancer agents].

Lilian Zsákai, Gábor Németh, Csaba Szántai-Kis, Zoltán Greff, Zoltán Horváth, Bálint Szokol, Ferenc Baska, Tin Chuad Boon, Lászlo Orfi, Györgya Kéri

Research output: Contribution to journalArticle

2 Citations (Scopus)


Fibroblast Growth Factor Receptor (FGFR) family is a sequentially highly related subgroup of membrane proteins consisting of four tyrosine kinase type enzyme: FGFR1, FGFR2, FGFR3 and FGFR4. These are kinases of great interest in a wide spectrum of physiological processes such as tissue repair via controlling cell proliferation. As initiatiors of cell proliferation, in some cases they have leading roles in several types of cancer, eg. breast cancer, pancreas cancer, gastric tumors and multiple myeloma via overexpression and/or mutation. This phenomenon makes them promising targets for drug development in order to develop signal transduction therapies based on small molecule FGFR inhibitors. We have developed two main groups of lead molecules: compounds with benzotiophene and oxindole cores utilizing numerous methods from in silico modelling via in vitro biochemichal assays and testing on relevant cell lines to cytotoxicity assays.

Translated title of the contribution[Developing FGFR inhibitors as potential anti-cancer agents].
Original languageHungarian
Pages (from-to)47-56
Number of pages10
JournalUnknown Journal
Issue number2
Publication statusPublished - 2013

ASJC Scopus subject areas

  • Pharmaceutical Science

Fingerprint Dive into the research topics of '[Developing FGFR inhibitors as potential anti-cancer agents].'. Together they form a unique fingerprint.

  • Cite this

    Zsákai, L., Németh, G., Szántai-Kis, C., Greff, Z., Horváth, Z., Szokol, B., Baska, F., Boon, T. C., Orfi, L., & Kéri, G. (2013). Potenciális antitumor hatású FGFR inhibitorok fejlesztése. Unknown Journal, 83(2), 47-56.